Longas Technologies Pty Ltd
Longas has developed Morphoseq™, a disruptive technology designed to dramatically improve the performance of industry-standard NGS platforms, by increasing effective read lengths, with benefits in accuracy and cost efficiency. Morphoseq effectively converts short read sequencers into virtual ‘long read’ sequencers, enabling finished-quality genome assemblies with high accuracy, including resolution of difficult-to-assemble genomic regions.
Longas is a spin out from the ithree institute at the University of Technology Sydney (UTS), initially based on research led by Professor Aaron Darling, a world-leading computational biologist and co-founders Professor Ian Charles and Dr. Catherine Burke. The Company was founded in 2015, operating in stealth mode until its public launch in May 2019.
Based in Sydney Australia, the Company is headed by renowned NGS leader, Nick McCooke and is funded by Australia’s Medical Research Commercialisation Fund (MRCF) and investment from the Company’s founders and directors.
The technology is nearing the final stages of validation and not currently available for end-users. Regular updates will be provided including new data that are generated using the platform.
Longas is actively seeking partners to support the commercial development of its technology.